001 LN Mar 2020

NICE formally adopts plan for real-world evidence utilisation

In January, a plan to use a broader range of evidence was formally adopted by NICE By using patient records and real-world evidence (such as registries and clinical audits), NICE anticipate improved guidance and sped-up recommendation updates While this is intended primarily for health and social care system guidance, it may also be extended to health […]

Read More
001 VN March 2020

Favipiravir delivers positive patient outcomes in COVID-19

“Zhang Xinmin, an official at China’s science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients. Patients who were given the medicine in Shenzhen turned negative for the virus after a median of four days after becoming positive, compared […]

Read More
001 BR Feb 2020

Real-world study shows inconsistency in haemophilia diagnosis rates

Many practitioners are aware that haemophilia is underdiagnosed; a real-world evidence study observed diagnosis rates varying in haemophilia A (16-47%) and haemophilia B (34-65%), showing an unmet need for more accurate and prevalent testing Many patients with haemophilia die before adulthood due to inadequate treatment; even with sufficient treatment, life expectancy in males is approximately […]

Read More
002 LN Feb 2020

NICE to increase use of real-world evidence

NICE plans to use more data resources than RCTs this year for submissions MHRA already takes account of real-world studies, in order to facilitate their upcoming 150 day licensing commitments The utilisation of real world data will be key in tackling the funding and access issue surrounding NICE reimbursement Click here to learn more About SVMPharma SVMPharma […]

Read More